Serveur d'exploration COVID et hydrochloroquine - Exploration (Accueil)

Index « AbsEn.i » - entrée « toxicity »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
toxicities < toxicity < toxicogenomic  Facettes :

List of bibliographic references indexed by toxicity

Number of relevant bibliographic references: 73.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000041 (2021) Keenan M. Mahan [États-Unis] ; Bryan D. Hayes [États-Unis] ; Crystal M. North [États-Unis] ; Justin S. Becker [États-Unis] ; Andrew Z. Fenves [États-Unis] ; Guibenson Hyppolite [États-Unis] ; Sara Khosrowjerdi [États-Unis] ; Daniel Sinden [États-Unis] ; Dana A. Stearns [États-Unis]Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity.
000067 (2021) Manel Ben Ali [Arabie saoudite] ; Amor Hedfi [Arabie saoudite] ; Mohammed Almalki [Arabie saoudite] ; Paraskevi K. Karachle [Grèce] ; Fehmi Boufahja [Tunisie]Toxicity of hydroxychloroquine, a potential treatment for COVID-19, on free-living marine nematodes.
000068 (2021) Cassandra Doyno [États-Unis] ; Diana M. Sobieraj [États-Unis] ; William L. Baker [États-Unis]Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.
000094 (2021) Subham Das [Inde] ; Anu Kunnath Ramachandran [Inde] ; Sumit Raosaheb Birangal [Inde] ; Saleem Akbar [Inde] ; Bahar Ahmed [Inde] ; Alex Joseph [Inde]The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review.
000269 (2021) Miguel Angel Martinez [Espagne]Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.
000271 (2021) Ahmed A. Ishola [Nigeria] ; Kayode E. Adewole [Nigeria] ; Habibu Tijjani [Nigeria] ; Suliat I. Abdulai [Nigeria] ; Nnaemeka T. Asogwa [Nigeria]Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs.
000279 (2021) Osama A. Badary [Égypte]Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs.
000330 (2021) Himanshu Rai [Inde] ; Atanu Barik [Inde] ; Yash Pal Singh [Inde] ; Akhil Suresh [Inde] ; Lovejit Singh [Inde] ; Gourav Singh [Inde] ; Usha Yogendra Nayak [Inde] ; Vikash Kumar Dubey [Inde] ; Gyan Modi [Inde]Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
000371 (2021) Serena Romani [France] ; Alexandre Gérard [France] ; Audrey Fresse [France] ; Delphine Viard [France] ; Élise Van-Obberghen [France] ; Joëlle Micallef [France] ; Fanny Rocher [France] ; Milou-Daniel Drici [France]Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic.
000426 (2021) Lucie Pothen [Belgique] ; Halil Yildiz [Belgique] ; Mathilde Mbouck Samnick [Royaume-Uni] ; Jean Cyr Yombi [Belgique]Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?
000438 (2021) Bugra Han Egeli [États-Unis] ; Jeffrey A. Sparks [États-Unis] ; Alfred H J. Kim [États-Unis] ; Jean W. Liew [États-Unis]Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?
000510 (2021) Smarajit Maiti [Inde] ; Amrita Banerjee [Inde]Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study.
000566 (2021) Xisheng Xiong [République populaire de Chine] ; Kun Wang [République populaire de Chine] ; Tao Tang [République populaire de Chine] ; Jinzhi Fang [République populaire de Chine] ; Yijun Chen [République populaire de Chine]Development of a chiral HPLC method for the separation and quantification of hydroxychloroquine enantiomers.
000570 (2021) Julia Werner [Allemagne] ; Raphael M. Kronberg [Allemagne] ; Pawel Stachura [Allemagne] ; Philipp N. Ostermann [Allemagne] ; Lisa Müller [Allemagne] ; Heiner Schaal [Allemagne] ; Sanil Bhatia [Allemagne] ; Jakob N. Kather [Allemagne] ; Arndt Borkhardt [Allemagne] ; Aleksandra A. Pandyra [Allemagne] ; Karl S. Lang [Allemagne] ; Philipp A. Lang [Allemagne]Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2.
000604 (2021) Guillaume Hache [France] ; Jean Marc Rolain [France] ; Philippe Gautret [France] ; Jean-Claude Deharo [France] ; Philippe Brouqui [France] ; Didier Raoult [France] ; Stéphane Honoré [France]Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
000655 (2021) Pierre Jordaan [Suisse] ; Bérengère Dumotier [Suisse] ; Martin Traebert [Suisse] ; Paul E. Miller [États-Unis] ; Andre Ghetti [États-Unis] ; Laszlo Urban [États-Unis] ; Najah Abi-Gerges [États-Unis]Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.
000656 (2021) Imad M. Tleyjeh [Arabie saoudite, États-Unis] ; Zakariya Kashour [Canada] ; Oweida Aldosary [Arabie saoudite] ; Muhammad Riaz [Pakistan] ; Haytham Tlayjeh [Arabie saoudite] ; Musa A. Garbati [Nigeria] ; Rana Tleyjeh [Arabie saoudite] ; Mouaz H. Al-Mallah [États-Unis] ; M Rizwan Sohail [États-Unis] ; Dana Gerberi [États-Unis] ; Aref A. Bin Abdulhak [États-Unis] ; John R. Giudicessi [États-Unis] ; Michael J. Ackerman [États-Unis] ; Tarek Kashour [Arabie saoudite]Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis.
000746 (2021) Andy On-Tik Wong [États-Unis] ; Bimal Gurung [Hong Kong] ; Wing Sum Wong [États-Unis] ; Suet Yee Mak [États-Unis] ; Wan Wai Tse [États-Unis] ; Chloe M. Li [Hong Kong] ; Deborah K. Lieu [États-Unis] ; Kevin D. Costa [États-Unis] ; Ronald A. Li [États-Unis] ; Roger J. Hajjar [États-Unis]Adverse effects of hydroxychloroquine and azithromycin on contractility and arrhythmogenicity revealed by human engineered cardiac tissues.
000780 (2021) Tien-Tzu Tai [Taïwan] ; Tzung-Ju Wu [Taïwan] ; Huey-Dong Wu [Taïwan] ; Yi-Chen Tsai [Taïwan] ; Hui-Ting Wang [Taïwan] ; An-Min Wang [Taïwan] ; Sheue-Fang Shih [Taïwan] ; Yee-Chun Chen [Taïwan]A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study.
000820 (2020) Hussain T. Bakhsh [Arabie saoudite]Hydroxychloroquine Toxicity Management: A Literature Review in COVID-19 Era.
000854 (2020) Paisan Ruamviboonsuk [Thaïlande] ; Timothy Y Y. Lai [République populaire de Chine] ; Andrew Chang [Australie] ; Chi-Chun Lai [Taïwan] ; William F. Mieler [États-Unis] ; Dennis S C. Lam [République populaire de Chine]Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i -k "toxicity" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i  \
                -Sk "toxicity" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    toxicity
}}

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021